Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
Single Patient Use of Tocilizumab for Treatment of Steroid Dependent, Active Systemic Onset Juvenile Idiopathic Arthritis
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Systemic onset Juvenile Idiopathic Arthritis (soJIA) is a type of arthritis (inflammation of the joints) that occurs with other symptoms including fever, swollen lymph nodes (glands), rash, and body aches. Because soJIA can be difficult to treat, children with soJIA can have severe problems from long-term use of steroids (prednisone). These problems include low bone density (weak bones), fractures, failure to grow properly, and large weight gain. The arthritis that occurs in soJIA often causes damage to many joints. This can make it hard to move around or do basic tasks like dressing. Also, a life-threatening illness called Macrophage Activation Syndrome (MAS) can occur when starting, stopping, or changing drugs that are used to treat soJIA.
SoJIA can be hard to treat and many children with soJIA do not respond to drugs that work for other kinds of arthritis. Research doctors have studied a chemical signal called IL-6 that the body uses to manage inflammation. This signal has been found to be very high in patients with active soJIA. A drug called tocilizumab (TCZ) has been designed to block IL-6. For about 6 years, TCZ has been tested in Japan for treating soJIA. It is now being tested in studies in the United States. These studies can have very strict rules for enrolling patients. This trial is a single-patient research study for a subject who otherwise does not meet the rules for enrollment in ongoing trials.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center/Floating Hospital for Children
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Systemic Juvenile Idiopathic Arthritis according to ILAR criteria (2001)
- Duration of disease ≥ 6 months since onset
- Presence of active disease as determined by the presence of at least 5 active joints, OR at least 2 active joints if receiving prednisone at a dose > 0.2 mg/kg/day or > 10 mg/day (whichever is less)
- Incomplete prior response to methotrexate treatment for at least 3 months at a minimum dose of 15 mg/M2/week, or intolerance to methotrexate
- Discontinued treatment with other biologics prior to first tocilizumab infusion, for approximately two pharmacokinetic half-lives as per specific biologic (e.g. 48 hours for anakinra, 7 days for etanercept)
- Not receiving corticosteroids, OR taking oral corticosteroids and the dose has remained stable for 1 week prior to the first tocilizumab infusion at ≤ 2 mg/kg/day prednisone or prednisolone and no more than 80 mg/day
Exclusion Criteria:
- Concomitant administration of biologic therapies
- Serum creatinine >1.5 ULN (upper limits normal)
- AST or ALT > 1.5 ULN
- Total bilirubin > 1.3 mg/dL
- Platelet count < LLN (lower limits normal)
- Hemoglobin < 6.0 g/dL
- WBC count < 5,000/mm3
- Neutrophil count < 2,000/ mm3
- Fibrinogen < LLN
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Tocilizumab
Single arm study - treatment only
|
Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks. Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Efficacy of Tocilizumab as Defined by Presence of an Equal to or Greater Than 30% Improvement in JIA Core Set (i.e. ACR JIA30 Response)
Prazo: At week 12 of treatment versus week 0 (pretreatment)
|
At week 12 of treatment versus week 0 (pretreatment)
|
|
|
Efficacy of Tocilizumab as Defined by Reduction of Oral Prednisone Dose by at Least 20%, or to Less Than 0.5mg/kg/Day, Whichever is of Lesser Daily Dose, While Maintaining an ACR JIA30 Response
Prazo: At weeks 12 and 16 of treatment versus week 0 (pretreatment)
|
At weeks 12 and 16 of treatment versus week 0 (pretreatment)
|
|
|
Number of Participants With at Least One Adverse Event
Prazo: Ongoing, throughout 24 month study period
|
To evaluate the safety of tocilizumab administration in this subject
|
Ongoing, throughout 24 month study period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Measurement of Laboratory Parameters of Active Disease, Specifically C-reactive Protein, Hemoglobin, Platelets, White Blood Cell Count, Ferritin, Immunoglobulins.
Prazo: At weeks 8, 12, and 16 of treatment, and every 8-12 weeks thereafter
|
To assess normalization of laboratory parameters of active disease, specifically C-reactive protein, hemoglobin, platelets, white blood cell
|
At weeks 8, 12, and 16 of treatment, and every 8-12 weeks thereafter
|
|
Measurement of Sustained Clinical Response to Tocilizumab, Including Active Joint Count, Joints With Limited Range of Motion, and Absence of Fever or Rash.
Prazo: At weeks 8, 12, 16 of treatment, and every 8 weeks thereafter
|
To assess sustained clinical response to tocilizumab, including active joint count, joints with limited range of motion, and absence of fever
|
At weeks 8, 12, 16 of treatment, and every 8 weeks thereafter
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Marc D Natter, MD, Tufts Medical Center
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TMC-PRHEU-TCZ-01
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Artrite Reumatoide Juvenil
-
Charles Drew University of Medicine and ScienceLos Angeles County Department of Public HealthRetiradoEquidade em saúde | Pesquisa-Ação Participativa Juvenil | Saúde Mental Juvenil
-
University of AarhusAarhus University HospitalConcluídoArtrite Reumatoide Juvenil Poliarticular | Artrite Idiopática Juvenil Sistêmica | Artrite Idiopática Juvenil, OligoartriteDinamarca
-
University of Illinois at ChicagoLaura and John Arnold Foundation; Big Brothers Big Sisters of America; Herrera... e outros colaboradoresAtivo, não recrutandoDelinquência juvenil | CrimeEstados Unidos
-
citiesRISEAfrican Population and Health Research Center; Schizophrenia Research Foundation...Inscrevendo-se por conviteSaúde Mental JuvenilÍndia, Quênia
-
NovartisConcluídoArtrite Reumatoide JuvenilItália
-
Novartis PharmaceuticalsConcluídoArtrite Idiopática Juvenil Sistêmica (AIJS)Itália, Federação Russa, Peru, Bélgica, Espanha, Alemanha, França, Israel, Canadá, Estados Unidos, Hungria, Áustria, Brasil, Suécia, Holanda, Polônia
-
GeneScience Pharmaceuticals Co., Ltd.Ainda não está recrutandoArtrite Idiopática Juvenil Sistêmica AtivaChina
-
Seattle Children's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) e outros colaboradoresConcluídoArtrite idiopática juvenil | Artrite Reumatóide Juvenil | Poliartrite Crônica JuvenilEstados Unidos
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationConcluídoArtrite idiopática juvenil sistêmica com exacerbação ativaEstados Unidos, Argentina, Canadá, Suíça, Alemanha, Israel, África do Sul, Bélgica, Itália, Espanha, França, Brasil, Peru, Hungria, Polônia, Noruega, Suécia, Holanda, Peru
-
University of Sao Paulo General HospitalAinda não está recrutandoArtrite idiopática juvenil | Artrite Reumatóide Juvenil | Artrite JuvenilBrasil
Ensaios clínicos em tocilizumab
-
Chinese PLA General HospitalRecrutamentoTumor Sólido | Malignidade HematológicaChina